Page last updated: 2024-10-23

aspirin and Shock

aspirin has been researched along with Shock in 38 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.

Research Excerpts

ExcerptRelevanceReference
"Diaspirin cross-linked hemoglobin (DCLHb) is a vasoactive hemoglobin-based oxygen carrier or "blood substitute" that has been shown to improve base deficit in several experimental studies of hemorrhagic shock."7.70The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. ( Hansbrough, JF; Soltero, RG, 1999)
"Diaspirin crosslinked hemoglobin (DCLHb; Baxter Healthcare Corp, Deerfield, IL) is hemoglobin-based oxygen carrier which, in our laboratory, improved hemodynamic parameters in a rat burn shock model."7.70Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model. ( Hansbrough, JF; Soltero, RG, 1999)
" Association of bronchial asthma, nasal pathology and intolerance to aspirin is a unique syndrome."4.75Aspirin intolerance--a review. ( Abrishami, MA; Thomas, J, 1977)
"Diaspirin cross-linked hemoglobin (DCLHb) is a vasoactive hemoglobin-based oxygen carrier or "blood substitute" that has been shown to improve base deficit in several experimental studies of hemorrhagic shock."3.70The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. ( Hansbrough, JF; Soltero, RG, 1999)
"Diaspirin crosslinked hemoglobin (DCLHb; Baxter Healthcare Corp, Deerfield, IL) is hemoglobin-based oxygen carrier which, in our laboratory, improved hemodynamic parameters in a rat burn shock model."3.70Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model. ( Hansbrough, JF; Soltero, RG, 1999)
"We describe a case of recurrent Kawasaki disease (KD) in a non-Asian 6-year-old boy who had been diagnosed with typical KD without cardiac involvement at age 3 years."1.40Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. ( Bœuf, B; Dauphin, C; Lang, M; Lusson, JR; Merlin, E; Tissandier, C, 2014)
"We report a 3-year-old girl with Kawasaki disease who presented with retropharyngeal edema and shock syndrome."1.40Unusual manifestations of Kawasaki disease with retropharyngeal edema and shock syndrome in a Taiwanese child. ( Chen, CK; Chu, SH; Fang, LC; Jim, WT; Kao, YH; Liu, LC; Peng, CC; Shyur, SD, 2014)
"The hypotension was found to be refractory to intravenous fluids, dopamine, and antihistamines, but was immediately reversed by intravenous epinephrine."1.26Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. ( Oates, JA; Roberts, LJ; Turk, JW, 1982)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-199020 (52.63)18.7374
1990's6 (15.79)18.2507
2000's2 (5.26)29.6817
2010's7 (18.42)24.3611
2020's3 (7.89)2.80

Authors

AuthorsStudies
Faraji, E1
Sukumaran, S1
Vijayan, V1
Cattalini, M1
Della Paolera, S1
Zunica, F1
Bracaglia, C1
Giangreco, M1
Verdoni, L1
Meini, A1
Sottile, R1
Caorsi, R1
Zuccotti, G1
Fabi, M1
Montin, D1
Meneghel, A1
Consolaro, A1
Dellepiane, RM1
Maggio, MC1
La Torre, F1
Marchesi, A1
Simonini, G1
Villani, A1
Cimaz, R1
Ravelli, A1
Taddio, A1
Gottlieb, M1
Bridwell, R1
Ravera, J1
Long, B1
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K1
Halvorsen, S1
Steg, PG1
Van de Werf, F1
Armstrong, PW1
Ma, L1
Zhang, YY1
Yu, HG1
Tissandier, C1
Lang, M1
Lusson, JR1
Bœuf, B1
Merlin, E1
Dauphin, C1
Camacho-Lovillo, MS1
Melón, M1
Moreno, MD1
Ardanuy, AV1
Neth, O1
Singletary, EM1
Zideman, DA1
De Buck, ED1
Chang, WT1
Jensen, JL1
Swain, JM1
Woodin, JA1
Blanchard, IE1
Herrington, RA1
Pellegrino, JL1
Hood, NA1
Lojero-Wheatley, LF1
Markenson, DS1
Yang, HJ1
Liang, CM1
Hsu, CN1
Tai, WC1
Yang, SC1
Wu, CK1
Shih, CW1
Ku, MK1
Yuan, LT1
Wang, JW1
Tseng, KL1
Sun, WC1
Hung, TH1
Nguang, SH1
Hsu, PI1
Wu, DC1
Chuah, SK1
Fang, LC1
Shyur, SD1
Peng, CC1
Jim, WT1
Chu, SH1
Kao, YH1
Chen, CK1
Liu, LC1
Wong, F1
KIMURA, Y1
MURANAKA, M1
BARNESS, LA2
YOUNG, LN2
Elad, S1
Chackartchi, T1
Shapira, L1
Findler, M1
Adams, HR1
Kootte, AM1
Haak, A1
Roberts, LJ2
Slichter, SJ1
Turk, JW1
Oates, JA1
Warne, PJ1
West, GB1
Saeed, SA1
Simjee, RU1
Mahmood, F1
Rahman, NN1
Chappell, JE2
McBride, WJ2
Shackford, SR2
Soltero, RG2
Hansbrough, JF2
Welter, HF1
Lauterjung, KL1
Isselhard, W1
Abrishami, MA1
Thomas, J1
Benowitz, NL1
Rosenberg, J1
Becker, CE1
Hormaechea, E1
Carlson, RW1
Rogove, H1
Uphold, J1
Henning, RJ1
Weil, MH1
Nelson, D1
Hai, T1
Srnak, A1
Ebeling, A1
Kunas, G1
Catarello, J1
Burhop, K1
Bahr, T1
Schaper, U1
Becker, K1
Lueddeckens, G1
Förster, W1
Scheuch, DW1
Grupe, R1
Seropian, E1
Allen, JE1
Valeri, CR1
Iurenev, PN1
Semenovich, NI1
Nelson, NC1
Nelson, JL1
Weldon, WE1
Vela, AR1
Adebahr, G1
Back, N1
Jainchill, M1
Wilkens, HJ1
Ambrus, JL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

Reviews

7 reviews available for aspirin and Shock

ArticleYear
Multisystem inflammatory syndrome in children with COVID-19.
    The American journal of emergency medicine, 2021, Volume: 49

    Topics: Adolescent; Adrenal Cortex Hormones; Aspirin; Child; Child, Preschool; COVID-19; Emergency Service,

2021
Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations.
    Circulation, 2015, Oct-20, Volume: 132, Issue:16 Suppl 1

    Topics: Airway Management; Aspirin; Asthma; Cardiopulmonary Resuscitation; Chest Pain; Emergencies; Emergenc

2015
Liver and kidney diseases.
    Clinics in liver disease, 2002, Volume: 6, Issue:4

    Topics: Acetaminophen; Anemia, Sickle Cell; Animals; Aspirin; Cholestasis; Cysts; Glomerulonephritis, IGA; G

2002
Pharmacologic problems in shock research.
    Advances in shock research, 1983, Volume: 10

    Topics: Adrenergic alpha-Antagonists; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Age

1983
Identification & management of defects in platelet hemostasis in massively transfused patients.
    Progress in clinical and biological research, 1982, Volume: 108

    Topics: Animals; Aspirin; Bleeding Time; Blood Preservation; Blood Transfusion; Cardiopulmonary Bypass; Cell

1982
Aspirin intolerance--a review.
    Annals of allergy, 1977, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Angioedema; Aspirin; Asthma; Blood Coagulation; Child; Child,

1977
Prostaglandins in hematology.
    Archives of internal medicine, 1974, Volume: 133, Issue:1

    Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Blood Preservation; Blood Transfusion; Chromiu

1974

Other Studies

31 other studies available for aspirin and Shock

ArticleYear
A 3 Year Old With Fever and Rash: An Atypical Cause of Shock.
    Clinical pediatrics, 2020, Volume: 59, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Diagnosis, Differential; Exanthe

2020
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
    Pediatric rheumatology online journal, 2021, Mar-16, Volume: 19, Issue:1

    Topics: Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; Child; Child, Preschool; Corona

2021
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Clinical Manifestations of Kawasaki Disease Shock Syndrome.
    Clinical pediatrics, 2018, Volume: 57, Issue:4

    Topics: Adolescent; Albumins; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Child;

2018
Kawasaki shock syndrome complicating a recurrence of Kawasaki disease.
    Pediatrics, 2014, Volume: 134, Issue:6

    Topics: Aspirin; Child; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug

2014
Kawasaki Disease Shock Syndrome (KDSS)--Presentation of 3 Children and Review of the Literature.
    Klinische Padiatrie, 2015, Volume: 227, Issue:6-7

    Topics: Adrenal Cortex Hormones; Aspirin; Child; Combined Modality Therapy; Female; Follow-Up Studies; Human

2015
Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study.
    Medicine, 2016, Volume: 95, Issue:36

    Topics: Adult; Age Factors; Aged; Aspirin; Female; Hemostasis, Endoscopic; Hospital Costs; Humans; Intubatio

2016
Unusual manifestations of Kawasaki disease with retropharyngeal edema and shock syndrome in a Taiwanese child.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2014, Volume: 47, Issue:2

    Topics: Aspirin; Cervix Uteri; Child, Preschool; Edema; Exanthema; Female; Fever; Humans; Immunoglobulins, I

2014
[SHOCK-LIKE SYMPTOMS CAUSED BY DRUGS AND THEIR TREATMENT. (1) BASIC PRINCIPLES].
    Jibi inkoka Otolaryngology, 1963, Volume: 35

    Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Anaphylaxis; Anti-Bacterial

1963
[SHOCK-LIKE SYMPTOMS CAUSED BY DRUGS AND THEIR TREATMENT. (2) CLINICAL ASPECTS].
    Jibi inkoka Otolaryngology, 1963, Volume: 35

    Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Blood Chemical Analysis; Body Constitut

1963
A SIMPLIFIED VIEW OF FLUID THERAPY.
    Pediatric clinics of North America, 1964, Volume: 11

    Topics: Acidosis; Adrenal Insufficiency; Aspirin; Calcium; Child; Cystic Fibrosis; Dehydration; Diabetes Mel

1964
A SIMPLIFIED VIEW OF FLUID THERAPY.
    Pediatric clinics of North America, 1964, Volume: 11

    Topics: Acidosis; Adrenal Insufficiency; Anuria; Aspirin; Body Weight; Burns; Calcium; Child; Cystic Fibrosi

1964
A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet.
    Journal of clinical periodontology, 2008, Volume: 35, Issue:4

    Topics: Aspirin; Clopidogrel; Drug Combinations; Female; Gingival Hemorrhage; Humans; Middle Aged; Periodont

2008
The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production.
    The Netherlands journal of medicine, 1983, Volume: 26, Issue:1

    Topics: Adult; Aspirin; Erythema; Humans; Hypotension; Male; Prostaglandin D2; Prostaglandins; Prostaglandin

1983
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks.
    Advances in shock research, 1982, Volume: 8

    Topics: Aspirin; Chlorpheniramine; Cimetidine; Epinephrine; Humans; Hypotension; Infusions, Parenteral; Pros

1982
Seasonal variation in drug action and animal responses in models of inflammation.
    International archives of allergy and applied immunology, 1980, Volume: 61, Issue:1

    Topics: Anaphylaxis; Animals; Aspirin; Cell Movement; Dextrans; Drug Resistance; Glucose; Inflammation; Leuk

1980
Dual inhibition of platelet-activating factor and arachidonic acid metabolism by ajmaline and effect on carrageenan-induced rat paw oedema.
    The Journal of pharmacy and pharmacology, 1993, Volume: 45, Issue:8

    Topics: Ajmaline; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Carbon Radioisotopes; Carrageenan; Ed

1993
Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after head injury and shock.
    The Journal of trauma, 1996, Volume: 41, Issue:5

    Topics: Animals; Aspirin; Blood Pressure; Brain Injuries; Cerebrovascular Circulation; Fluid Therapy; Hemody

1996
Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after head injury and shock.
    Journal of neurosurgery, 1997, Volume: 86, Issue:1

    Topics: Animals; Aspirin; Blood Pressure; Body Water; Cardiac Output; Central Venous Pressure; Cerebral Cort

1997
The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats.
    The Journal of trauma, 1999, Volume: 46, Issue:2

    Topics: Acidosis; Animals; Aspirin; Burns; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therap

1999
Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model.
    Artificial cells, blood substitutes, and immobilization biotechnology, 1999, Volume: 27, Issue:2

    Topics: Animals; Aspirin; Blood Substitutes; Blood Transfusion; Burns; Hemodynamics; Hemoglobins; Male; Rats

1999
Inhibition of platelet aggregation during hypovolemic hypotension by acetylsalicylic acid and artificial respiration.
    Bibliotheca anatomica, 1979, Issue:18

    Topics: Adenosine Diphosphate; Animals; Aspirin; Dogs; Histamine Release; Hypotension; Platelet Aggregation;

1979
Cardiopulmonary catastrophes in drug-overdosed patients.
    The Medical clinics of North America, 1979, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Amphetamines; Antidepressive Agents; Arrhythmias, Cardiac; Aspirin; Cardiovascula

1979
Hypovolemia, pulmonary edema and protein changes in severe salicylate poisoning.
    The American journal of medicine, 1979, Volume: 66, Issue:6

    Topics: Adult; Aspirin; Blood Pressure; Blood Proteins; Blood Volume; Female; Hematocrit; Humans; Hypoprotei

1979
Synthesis and properties of polymerized, diaspirin cross-linked hemoglobins.
    Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology, 1992, Volume: 20, Issue:2-4

    Topics: Animals; Aspirin; Blood Substitutes; Chlorocebus aethiops; Cross-Linking Reagents; Drug Evaluation,

1992
Influence of inhibitors of the eicosanoid metabolism, and of eicosanoids- and PAF-acether antagonists on mortality and some biochemical parameters of three shock models.
    Progress in clinical and biological research, 1989, Volume: 301

    Topics: Anaphylaxis; Animals; Aspirin; Diterpenes; Fatty Acids, Unsaturated; Female; Ginkgolides; Imidazoles

1989
[Clinical aspects of drug allergy].
    Medicina interna, 1967, Volume: 19, Issue:12

    Topics: Adolescent; Adult; Anaphylaxis; Aspirin; Asthma; Chloramphenicol; Drug Eruptions; Drug Hypersensitiv

1967
[Desensitization therapy in myocardial infarct].
    Kardiologiia, 1970, Volume: 10, Issue:1

    Topics: Adrenal Glands; Amines; Aminopyrine; Aspirin; Autoimmune Diseases; Desensitization, Immunologic; Dip

1970
Mechanisms of change in thoracic duct lymph flow during hypotensive states.
    Annals of surgery, 1970, Volume: 171, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aspirin; Capillary Permeability;

1970
[Therapy in decompression sickness and air embolism].
    Zeitschrift fur Rechtsmedizin. Journal of legal medicine, 1971, Volume: 68, Issue:5

    Topics: Abortion, Spontaneous; Adult; Air; Animals; Arteries; Aspirin; Blood Platelets; Capillaries; Child;

1971
Effect of inhibitors of plasmin, kallikrein and kinin on mortality from scalding in mice.
    Medicina et pharmacologia experimentalis. International journal of experimental medicine, 1966, Volume: 15, Issue:6

    Topics: Aminocaproates; Animals; Aprotinin; Aspirin; Burns; Enzyme Therapy; Male; Mice; Phenylbutazone; Sali

1966